Interestingly, both EOs were able to significantly reduce TNF-α-induced NF-κB p65 cytoplasm–nucleus translocation in both C- and GDM-HUVEC, thus confirming the capability of AEO and LEO in reducing vascular inflammation in vitro. The gene discussed is NFKB1; the disease is gestational diabetes.